Roy Fleischmann, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center, discusses with Rheumatology Advisor results from the EXXELERATE trial (Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Inadequately Responding to Methotrexate; ClinicalTrials.gov Identifier: NCT01500278).
Data from this trial suggest that immediately switching from one tumor necrosis factor (TNF) inhibitor to another inhibitor was safe in those who had primary TNFi failure, even without a drug washout period.
Fleischmann R, Burmester GR, Combe B, et al. Efficacy and safety of switching between certolizumab pegol and adalimumab after primary anti-TNF treatment failure: 2-Year results from a randomized, investigator-blind, superiority head-to-head study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/efficacy-and-safety-of-switching-between-certolizumab-pegol-and-adalimumab-after-primary-anti-tnf-treatment-failure-2-year-results-from-a-randomized-investigator-blind-superiority-head-to-head-stud/. Accessed November 28, 2016.